Publications by authors named "J M Ortega"

In the rapidly growing field of psychedelic research, psilocybin (and active metabolite psilocin) has been proposed as a promising candidate in the search for novel treatments for neuropsychiatric disorders. Clinical trials have revealed that psilocybin has a large, rapid, and persistent effect in the improvement of symptoms of depression and anxiety. The safety profile is considered favourable, with low toxicity and good tolerance.

View Article and Find Full Text PDF

Unlike other mammals, bats serve as natural reservoirs for several highly pathogenic viruses without exhibiting symptoms of infection. Recent research has explored the complex mechanisms underlying the balance between bats' antiviral defenses and their pathological responses. However, the evolution of the molecular drivers behind bats' antiviral strategies remains largely unknown.

View Article and Find Full Text PDF

Type 1 Diabetes Mellitus (T1D) is an autoimmune disease caused by unremitting immune attack on pancreas insulin-producing beta cells. Persistence of the autoimmune response is mediated by TCF1+ Ly108+ progenitor CD8+ T (T) cells, a stem-like population that gives rise to exhausted effectors with limited cytolytic function in chronic virus infection and cancer. What paradoxically drives T conversion to highly cytolytic effectors in T1D, however, remains unclear.

View Article and Find Full Text PDF
Article Synopsis
  • High-dose methotrexate (MTX) can lead to serious complications like acute kidney injury (AKI), neutropenia, and liver damage, but glucarpidase, an enzyme that breaks down MTX, shows potential benefits.
  • In a study of 708 patients with MTX-AKI across 28 cancer centers, those receiving glucarpidase had a significantly higher chance of kidney recovery and faster recovery times compared to those who did not receive the treatment.
  • Additionally, glucarpidase treatment was associated with lower rates of severe neutropenia and liver enzyme elevation, but there was no notable difference in mortality rates between the two groups.
View Article and Find Full Text PDF

Uganda started implementing mass drug administration against schistosomiasis in 2003, with district used as an implementation unit. This resulted into misclassification of communities into wrong risk levels, under-or-over treatment and over request of praziquantel (PZQ) drugs. The objective of the current study was to reviewing the community data available at World Health Organization/ESPEN database to understand the status of schistosomiasis and identify pockets with infection.

View Article and Find Full Text PDF